Two-year follow-up of a thyroid cartilage metastasis from prostate cancer: A case report

dc.contributor.authorKobeissi, Jana M.
dc.contributor.authorYoussef, Bassem Y.
dc.contributor.authorMobayed, Tala
dc.contributor.departmentRadiation Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:12:27Z
dc.date.available2025-01-24T12:12:27Z
dc.date.issued2023
dc.description.abstractFew case reports describe metastatic prostate cancer to the thyroid cartilage. While earlier reports identified the metastatic lesions upon developing symptoms, more recent ones have detected them via prostate-specific membrane antigen positron emission tomography (PSMA PET). Herein, we report the case of a patient with metastatic castrate-resistant prostate cancer and a PSMA PET-detected lesion in the thyroid cartilage. Over the course of 2 years, he received multiple lines of chemotherapy and hormonal therapy, and his overall disease status fluctuated — some nodal and bony metastases resolved while others appeared anew. His thyroid cartilage lesion, however, slowly progressed in a consistent fashion with increasing uptake on successive PSMA PET images. Apart from mild dysphonia, the patient remained to be asymptomatic from this lesion, and no local therapies were used. To our knowledge, this is the first close follow-up of prostate cancer metastatic to the thyroid cartilage, shedding light on the course of such lesions and helping answer management-related questions, which are particularly relevant as more occult metastases are discovered in the PSMA PET era. © 2023
dc.identifier.doihttps://doi.org/10.1016/j.radcr.2023.07.071
dc.identifier.eid2-s2.0-85168369343
dc.identifier.urihttp://hdl.handle.net/10938/32778
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofRadiology Case Reports
dc.sourceScopus
dc.subjectLaryngeal metastases
dc.subjectOccult metastases
dc.subjectProstate adenocarcinoma
dc.subjectPsma pet
dc.subjectCabazitaxel
dc.subjectDocetaxel
dc.subjectEnzalutamide
dc.subjectFluorodeoxyglucose
dc.subjectProstate specific membrane antigen
dc.subjectTestosterone
dc.subjectTracer
dc.subjectAdult
dc.subjectAndrogen deprivation therapy
dc.subjectArticle
dc.subjectAsymptomatic disease
dc.subjectBody weight loss
dc.subjectBone metastasis
dc.subjectCancer chemotherapy
dc.subjectCancer hormone therapy
dc.subjectCancer patient
dc.subjectCase report
dc.subjectClinical article
dc.subjectDisease duration
dc.subjectDisease exacerbation
dc.subjectDysphonia
dc.subjectFollow up
dc.subjectGleason score
dc.subjectHuman
dc.subjectLymph node metastasis
dc.subjectMale
dc.subjectMetastatic castration resistant prostate cancer
dc.subjectMiddle aged
dc.subjectMultiple cycle treatment
dc.subjectOncology
dc.subjectPalliative therapy
dc.subjectPositron emission tomography-computed tomography
dc.subjectRadiation oncology
dc.subjectThyroid cartilage
dc.subjectThyroid metastasis
dc.titleTwo-year follow-up of a thyroid cartilage metastasis from prostate cancer: A case report
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-402.pdf
Size:
939.84 KB
Format:
Adobe Portable Document Format